Literature DB >> 15824741

A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors.

Lei L Chen1, Mahyar Sabripour, Elsie F Wu, Victor G Prieto, Gregory N Fuller, Marsha L Frazier.   

Abstract

We report a new mechanism of aberrant pre-mRNA splicing resulting in constitutive activation of a mis-spliced oncoprotein (KIT) leading to malignancy (gastrointestinal stromal tumor) in contrast to loss of function of mis-spliced proteins resulting in diverse human diseases in the literature. The mechanisms of three consecutive molecular events, deletion of noncoding and coding regions encompassing the 3' authentic splice site, creation of a novel intra-exonic pre-mRNA 3' splice acceptor site leading to in-frame loss of 27 nucleotides (nine amino acids; Lys550-Lys558), and the mechanism of constitutive activation of the mis-spliced KIT are elucidated. Loss of a peptide in a critical location unleashed the protein from autoinhibition (as evidenced by three-dimensional structural analysis), causing KIT to become constitutively activated and resulting in the GIST phenotype. We also demonstrated that only one of the following two exonic splicing enhancers is sufficient for inclusion of the KIT exon 11 in vivo: AACCCATGT (nucleotides 2-10 from the 5' end, which are recognized by SC35, SRp55, and SF2/ASF) or GGTTGTTGAGG (nucleotides 27-37 from the 5' end, which are recognized by SC35 and SRp55), suggestive of exonic enhancer redundancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824741     DOI: 10.1038/sj.onc.1208587

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation.

Authors:  Alberto Zamò; Anna Bertolaso; Ilaria Franceschetti; Gregor Weirich; Paola Capelli; Sara Pecori; Marco Chilosi; Heinz Hoefler; Fabio Menestrina; Aldo Scarpa
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

2.  hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration.

Authors:  Kim Moran-Jones; Joan Grindlay; Marc Jones; Ross Smith; Jim C Norman
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 3.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

Review 4.  The pathobiology of splicing.

Authors:  Amanda J Ward; Thomas A Cooper
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

5.  Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.

Authors:  Peter S Choi; Yulin Li; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

Review 6.  Alternative tumour-specific antigens.

Authors:  Christof C Smith; Sara R Selitsky; Shengjie Chai; Paul M Armistead; Benjamin G Vincent; Jonathan S Serody
Journal:  Nat Rev Cancer       Date:  2019-07-05       Impact factor: 60.716

7.  Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Authors:  Sabine Druillennec; Coralie Dorard; Alain Eychène
Journal:  J Nucleic Acids       Date:  2011-10-05

8.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

9.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.

Authors:  Fabien Reyal; Martin H van Vliet; Nicola J Armstrong; Hugo M Horlings; Karin E de Visser; Marlen Kok; Andrew E Teschendorff; Stella Mook; Laura van 't Veer; Carlos Caldas; Remy J Salmon; Marc J van de Vijver; Lodewyk F A Wessels
Journal:  Breast Cancer Res       Date:  2008-11-13       Impact factor: 6.466

10.  Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Authors:  Line Wergeland; Gry Sjøholt; Ingvild Haaland; Randi Hovland; Øystein Bruserud; Bjørn Tore Gjertsen
Journal:  Mol Cancer       Date:  2007-05-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.